HONG KONG -- Hong Kong biotechnology startup Prenetics is set to be absorbed by a New York-listed special purpose acquisition company backed by New World Development Chief Executive Adrian Cheng.
The deal with Cheng's Artisan Acquisition SPAC will value Prenetics, known for its COVID-19 screening work for the English Premier League as well as Hong Kong International Airport and London Heathrow Airport, at about $1.3 billion, according to three people familiar with the deal.
